))
Is the FDA’s Response to AI Falling Behind?
Manage episode 455472807 series 3506216
محتوای ارائه شده توسط Darshan Kulkarni. تمام محتوای پادکست شامل قسمت‌ها، گرافیک‌ها و توضیحات پادکست مستقیماً توسط Darshan Kulkarni یا شریک پلتفرم پادکست آن‌ها آپلود و ارائه می‌شوند. اگر فکر می‌کنید شخصی بدون اجازه شما از اثر دارای حق نسخه‌برداری شما استفاده می‌کند، می‌توانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal
The FDA’s current approach to AI in healthcare highlights significant gaps in regulatory preparedness. Although the FDA has approved thousands of AI-enabled tools, it still lacks the resources, clear guidelines, and enforcement power necessary to address the rapid advancements and risks of AI effectively. The agency has issued frameworks and adopted some risk-based approaches, but these efforts fall short, leaving companies in limbo and patient safety at risk. AI in healthcare demands consistent oversight, yet the FDA’s “wait-and-watch” approach, often leading to delayed action, hinders industry progress and creates uncertainty for innovators. Addressing these issues requires urgent congressional support, funding, and global regulatory collaboration. At the Kulkarni Law Firm, we help guide companies through this complex regulatory landscape to ensure compliance and safety. For more insights, subscribe to our podcast or reach out today.
148 قسمت
اشتراک گذاری
